Related Experiment Video

Updated: Jun 26, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Long-term cost-effectiveness of disease management in systolic heart failure

George Miller1, Stephen Randolph, Emma Forkner

  • 1Altarum Institute, Ann Arbor, MI 48113-4001, USA. george.miller@altarum.org

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|January 17, 2009
PubMed

Insights

Disease management for congestive heart failure (CHF) patients extends lifespan by 51 days. While increasing costs, this approach proves cost-effective long-term, offering valuable insights for healthcare management.

Area of Science:

  • Cardiology
  • Health Economics
  • Medical Informatics

Background:

  • Congestive heart failure (CHF) management programs show mixed results on effectiveness and cost-savings.
  • Previous studies lack long-term projections for CHF disease management.

Purpose of the Study:

  • To estimate the long-term impact of systolic heart failure disease management.
  • To project lifetime costs and clinical benefits using clinical trial data.

Main Methods:

  • A Markov model was employed, utilizing data from an 18-month clinical trial.
  • Model inputs included population distributions, resource use, mortality, and transition probabilities.
  • Cost-effectiveness was calculated as cost per quality-adjusted life year (QALY) gained, with a 3% discount rate.

Main Results:

  • Lifetime lifespan extension of 51 days was projected for patients in the disease management group.
  • Discounted lifetime costs were $4850 higher, but cost-effectiveness was favorable at $43,650/QALY.
  • Results remained robust across various sensitivity analyses.

Conclusions:

  • Model-based analyses enhance the estimation of clinical benefits and financial burden of disease management.
  • Long-term disease management of heart failure patients is suggested to be cost-effective.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...